InvestorsHub Logo
Followers 405
Posts 2400
Boards Moderated 2
Alias Born 09/05/2013

Re: None

Saturday, 08/26/2017 2:00:01 PM

Saturday, August 26, 2017 2:00:01 PM

Post# of 646
I'm sure the financials will be steady and the cash position over $20-30m, but more interested in patient number increases and guidance on divisions... mainly Biotech. They have John Stewart who was ceo of Purdue pharma (makers of OxyContin), it's time to unleash him...

http://www.bbc.com/news/amp/world-us-canada-38083737